0.9  0.079 (9.62%)		07-26 16:00
Open: 0.84 High: 0.9 Volume: 41,701		Pre. Close: 0.821 Low: 0.84 Market Cap: 3(M)

Short term
Mid term
Targets	6-month :	1.12	1-year :	1.3
Resists	First :	0.95	Second :	1.12
Pivot price	0.84
Supports	First :	0.81	Second :	0.72
MAs	MA(5) :	0.84	MA(20) :	0.85
	MA(100) :	1.21	MA(250) :	29.72
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	63.6	D(3) :	40.4
RSI	RSI(14): 51.2
52-week	High :	196	Low :	0.72

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TCBP ] has closed below upper band by 7.9%. Bollinger Bands are 76.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.9 - 0.9	0.9 - 0.91
Low:	0.83 - 0.84	0.84 - 0.84
Close:	0.89 - 0.9	0.9 - 0.91

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Fri, 28 Jun 2024
TC Biopharm Board Members Resign Suddenly - TipRanks

Thu, 04 Apr 2024
TC BioPharm eyes expansion with CAR-NK technology LOI - Investing.com

Thu, 04 Apr 2024
TC Biopharm shares jump on signing non-binding LOI for two allogeneic CAR-NK therapeutics - Seeking Alpha

Wed, 13 Mar 2024
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP - WICZ

Fri, 01 Mar 2024
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" - PR Newswire

Fri, 09 Feb 2024
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Markets Insider

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	9.835e+007 (%)
Held by Institutions	0 (%)
Shares Short	57 (K)
Shares Short P.Month	0 (K)

EPS	-1.292e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-109 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	2718.5
EBITDA (p.s.)	0
Qtrly Earnings Growth	-19.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0.21

Dividend	0
Forward Dividend	14340
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.